Armata Pharmaceuticals, Inc. financial data

Symbol
ARMP on NYSE
Industry
Biological Products, (No Diagnostic Substances)
Location
5005 Mcconnell Ave, Los Angeles, California
State of incorporation
Washington
Fiscal year end
December 31
Former names
AmpliPhi Biosciences Corp (to 5/8/2019), TARGETED GENETICS CORP /WA/ (to 2/11/2011)
Latest financial report
Q1 2024 - May 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 62.2 % -59.8%
Debt-to-equity -629 % -511%
Return On Equity 389 %
Return On Assets -73.6 % -71.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.1M shares +0.01%
Common Stock, Shares, Outstanding 36.1M shares -0.04%
Entity Public Float 12.5M USD -70.2%
Common Stock, Value, Issued 361K USD 0%
Weighted Average Number of Shares Outstanding, Basic 36.1M shares +0.22%
Weighted Average Number of Shares Outstanding, Diluted 36.1M shares +0.22%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 12.3M USD +53.8%
Operating Income (Loss) -39.8M USD -0.65%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -69K USD -87%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -79.6M USD -86.7%
Earnings Per Share, Basic -2.2 USD/shares -86.4%
Earnings Per Share, Diluted -2.2 USD/shares -86.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 37.9M USD +50.8%
Other Assets, Current 1.71M USD
Assets, Current 41.7M USD +8.09%
Property, Plant and Equipment, Net 12.7M USD +134%
Operating Lease, Right-of-Use Asset 44.2M USD +3.3%
Intangible Assets, Net (Excluding Goodwill) 10.3M USD 0%
Goodwill 3.49M USD 0%
Other Assets, Noncurrent 2.47M USD +0.69%
Assets 120M USD +10.6%
Accounts Payable, Current 2.06M USD
Liabilities, Current 110M USD +114%
Deferred Income Tax Liabilities, Net 3.08M USD 0%
Operating Lease, Liability, Noncurrent 28.4M USD -10.9%
Liabilities 177M USD +105%
Retained Earnings (Accumulated Deficit) -334M USD -31.3%
Stockholders' Equity Attributable to Parent -56.5M USD -352%
Liabilities and Equity 120M USD +10.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.6M USD +39.8%
Net Cash Provided by (Used in) Financing Activities 34.9M USD +18%
Net Cash Provided by (Used in) Investing Activities -250K USD +87.6%
Common Stock, Shares Authorized 217M shares 0%
Common Stock, Shares, Issued 36.1M shares -0.04%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 24.1M USD +141%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 43.3M USD +40.6%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Operating Lease, Liability 35.9M USD
Depreciation 1.1M USD +25.9%
Payments to Acquire Property, Plant, and Equipment 250K USD -87.6%
Lessee, Operating Lease, Liability, to be Paid 71.8M USD
Property, Plant and Equipment, Gross 24.8M USD +48.1%
Operating Lease, Liability, Current 7.5M USD -42.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.31M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 6.54M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 36M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.47M USD
Current Income Tax Expense (Benefit) 0 USD
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.45M USD
Operating Lease, Payments 3.36M USD -35.4%
Additional Paid in Capital 277M USD +0.22%
Depreciation, Depletion and Amortization 317K USD +37.8%
Share-based Payment Arrangement, Expense 615K USD -82.3%
Interest Expense 1.82M USD